Firmagon Generic Name & Formulations
Degarelix 80mg/vial, 120mg/vial; pwd for SC inj after reconstitution.
Treatment Initiation pack (120mg/vial)—2 (w. supplies); Treatment Maintenance pack (80mg/vial)—1 (w. supplies)
Advanced prostate cancer.
Firmagon Dosage and Administration
Give by SC inj in abdomen once every 28 days; avoid waist and rib areas. Two 120mg injections once, then one 80mg inj once every 28 days.
Firmagon Boxed Warnings
Congenital long QT syndrome. CHF. Correct electrolyte abnormalities. Monitor electrolytes and ECG periodically. Monitor serum PSA. Discontinue if serious hypersensitivity reaction occurs; do not rechallenge. Moderate or severe renal impairment (CrCl <50mL/min). Severe hepatic impairment. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.
Caution with concomitant drugs known to prolong the QT interval.
Firmagon Adverse Reactions
Inj site reactions (eg, pain, erythema, swelling, induration), hot flashes, increased weight, fatigue, increased transaminases, increased gamma-glutamyltransferase; QT prolongation.
Firmagon Clinical Trials
Firmagon Patient Counseling